木瓜直播

It may be possible to detect ovarian cancer of actual symptom onset based on the molecular and genetic analysis of cells taken from routine Pap tests. (Science Translational Medicine)

A six-patient clinical trial involving non-small cell lung cancer (NSCLC) patients suggested that -- an interleukin-4/13 inhibitor widely used to treat allergic conditions such as eczema and asthma -- may boost the anti-cancer immune response. (Nature)

Rep. Glenn Thompson (R-Pa.) announced he has been . (The Hill)

the Biden administration's cancer moonshot goals. (Politico)

Liver elastography can be an effective and non-invasive method of in patients with cirrhosis secondary to chronic hepatitis C. (Clinical Gastroenterology and Hepatology)

A New Jersey medical student is undergoing treatment for papillary thyroid cancer discovered when she was . (ABC News)

The U.S. Air Force is expanding its study on the high rates of cancers reported in . (ABC News)

Sanofi said its phase III in transplant-ineligible patients with newly diagnosed multiple myeloma met its primary endpoint, showing that the addition of isatuximab (Sarclisa) to bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone improved progression-free survival (PFS) versus the standard three-drug regimen alone.

Nivolumab (Opdivo) plus ipilimumab (Yervoy) improved PFS versus chemotherapy in metastatic colorectal cancer patients with microsatellite instability-high or mismatch repair-deficient disease in an interim analysis of the , Bristol Myers Squibb announced.

Roche announced that a phase III trial testing first-line treatment in PIK3CA-mutated, hormone-receptor positive/HER2-negative breast cancer met , with the investigational PI3K alpha inhibitor inavolisib improving PFS when combined with palbociclib (Ibrance) and fulvestrant (Faslodex).

Meanwhile, Merck said that in previously metastatic NSCLC, its anti-TIGIT drug vibostolimab when added to pembrolizumab (Keytruda) in a phase II study.

Comment